BGI Genomics
2025.09.22
20:11
BGI: Shareholding ratio passively diluted to 31.3223%
BGI announced that its disclosure obligor, BGI Holdings, and its concerted parties, BGI Sanshengyuan and Wang Jian, collectively hold 131 million shares of the company, representing 31.3223% of the company's total share capital. This equity change resulted from the passive dilution of the disclosure obligor's shareholdings due to the increase in the company's total share capital following the issuance of shares to specific investors and the completion of the registration of the vesting of the second class of restricted shares under the 2022 Restricted Stock Incentive Plan. The disclosure obligor has no specific plans, agreements, or arrangements to increase or decrease its interest in the listed company within the next 12 months.
2025.09.15
17:05
BGI: Shareholders inquire about the transfer price at 44.1 yuan per share
BGI Genomics announced that based on the subscription results from the inquiry on September 15, 2025, the preliminary transfer price for the company's shareholder, Shenzhen BGI Genomics Technology Co., Ltd., is RMB 44.1 per share. This inquiry transfer is a private sale, not conducted through a centralized auction or block trade, and does not constitute a reduction in holdings in the secondary market. The transferee cannot transfer the shares acquired through the inquiry transfer within six months of the acquisition. The transferee of this inquiry transfer is an institutional investor with appropriate pricing power and risk tolerance.
2025.09.09
19:07
BGI: Shenghua Investment's stake reduced to 7.9413%
BGI announced that Shenzhen Shenghua Investment Enterprise (Limited Partnership), a shareholder holding more than 5% of the shares, reduced its holdings of the company's shares by 1.2507 million shares through centralized bidding from September 4, 2025 to September 8, 2025, accounting for 0.2990% of the company's total share capital. Its shareholding ratio dropped from 8.2403% to 7.9413%. This equity change reached an integer multiple of 1%, and the reduction plan has not yet been fully implemented.
2025.07.05
16:08
26 Shenzhen companies will form a group to participate in the Chain Expo
According to Shenzhen Special Zone Daily, the reporter learned on the 4th that 26 industry benchmarking companies organized by the Shenzhen Trade Promotion Council will form a Shenzhen exhibition group to participate in the 3rd China International Supply Chain Promotion Expo (hereinafter referred to as "Chain Expo"), which will be opened in Beijing on July 16, with open cooperation as the link to fully demonstrate the innovative charm of "Shenzhen Smart Manufacturing". Among the participating Shenzhen companies, high-quality companies such as WenJian Medical, BGI, Youhe Group, ZTE, UBTECH, SenseTime, and DJI Innovations are all on the list, spanning advanced manufacturing, digital technology, healthy life, green agriculture, smart cars, clean energy, and supply chain services. "6 chains and 1 exhibition area" will fully present the innovative vitality and super resilience of Shenzhen's industrial chain, and seek new opportunities for supply chain development with global partners in an open attitude.
2025.05.23
10:28
The unusual movement of AI medical sector pushed Berry Genomics to the daily limit
The AI medical sector rose abnormally, Berry Genomics hit its daily limit, and Cellix Medical, BGI, Dian Diagnostics, Winning Health, KingMed Medical, and Huakang Cleanliness all rose.
2025.05.13
14:11
The A-share medical services sector continued to rise, with BGI rising by more than 10%, Dian Diagnostics and Berry Genomics rising by more than 7%, and KingMed Diagnostics and Meinian Health following suit.
14:05
The medical services sector continued to rise, with BGI rising by more than 10%
The medical services sector continued to rise, with BGI rising by more than 10%, Dian Diagnostics and Berry Genomics rising by more than 7%, and KingMed Diagnostics and Meinian Health following suit.
13:53
The A-share healthcare sector rose, Shangrong Medical hit its daily limit, Jiaoda Anli had previously hit its daily limit, and BGI, Anping, Dian Diagnostics and others were among the top gainers.
2025.04.26
01:22
BGI: Net loss of 52.6951 million yuan in the first quarter of 2025
BGI announced that its operating income in the first quarter of 2025 was 672 million yuan, a year-on-year decrease of 18.18%. Its net loss was 52.6951 million yuan, compared with a net profit of 12.4025 million yuan in the same period last year.
2025.03.07
17:31
Novogene: Signed a strategic cooperation agreement with BGI
Novazonics announced that it has signed a strategic cooperation agreement with BGI. The two parties will cooperate in the fields of reproductive genetics, tumor prevention and control, chronic disease management and infection prevention and control, and promote genomics from basic research to clinical medicine. The cooperation period is 5 years, from March 6, 2025 to March 5, 2030. The specific details of the cooperation will be subject to the signing of subsequent agreements. This cooperation is not expected to have a significant impact on the company's 2025 annual performance, and the impact on the company's future annual operating performance will depend on the specific cooperation situation in the future.
13:46
BGI and Novozymes Sign Cooperation Agreement
On March 6, BGI and Nanjing Novaeda Biotech Co., Ltd. ("Novaeda") officially signed a cooperation agreement. The two parties will focus on the fields of life sciences and in vitro diagnostics, aiming to jointly promote technological innovation and product application through complementary advantages, inject new impetus into the development of brain science and brain health, and create a new paradigm for the coordinated development of China's biotechnology.
2025.03.04
13:30
A-share gene sequencing concept stocks were locally active, with BGI Genomics rising more than 14%. Berry Genomics had previously hit the daily limit, followed by BGI, Daan Genetics, Dian Diagnostics and others.
13:27
Gene sequencing stocks were active locally, with BGI rising by more than 14%
Gene sequencing concept stocks were locally active, with BGI Genomics rising more than 14%. Berry Genomics had previously hit the daily limit, followed by BGI, Daan Genetics, Dian Diagnostics and others.
2025.03.01
11:54
What is the future profit model of the launched AI big model? BGI responds
Regarding the question of "the future profit model of the AI big model launched by the company", BGI stated during the institutional survey that BGI AI big model will consider cooperating with the hospital side in the future and give birth to diversified product forms and innovative business models. In terms of product form, it is possible to combine artificial intelligence technology with hospital diagnosis and treatment services through applications and other forms to provide users with personalized health testing assessments, disease warnings and diagnosis and treatment recommendations; in terms of profit model, in the future, the company considers achieving profitability by exporting big model technology to customers or providing services, which depends on product positioning and service content.
2025.02.26
19:23
Chinese business delegation visits Saudi Arabia
According to the China Council for the Promotion of International Trade, the China Council for the Promotion of International Trade organized a delegation of Chinese entrepreneurs to visit Saudi Arabia from February 25 to 27 to actively promote economic and trade exchanges between China and Saudi Arabia and deepen mutually beneficial and pragmatic cooperation between the business communities of the two countries. The delegation focused on introducing China's economic situation and the latest measures to expand opening up to Saudi political and business people, actively promoting the deepening and implementation of the "Belt and Road" initiative between China and Saudi Arabia, further deepening the cooperation between the business communities of the two countries in the field of industrial chain and supply chain, and welcomed Saudi Arabia to actively participate in the third Chain Expo. Business people in China and Saudi Arabia generally believe that the economic and trade cooperation between the two sides has great potential and broad prospects. Enterprises and institutions of both sides actively carried out business negotiations and achieved a number of cooperation results. During the visit, Yu Jianlong, Vice President of the China Council for the Promotion of International Trade, led a delegation of Chinese entrepreneurs to visit the Federation of Saudi Chambers of Commerce and Saudi Basic Industries Corporation, investigate Saudi Dragon City, BGI Saudi Precision Medicine Laboratory, etc., and held two exchange activities, the China-Saudi Entrepreneurs Symposium and the China-Saudi Entrepreneurs Roundtable.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Musk: XAI will certainly raise funds in the next few months, but not now

2025-09-20

Nvidia (NVDA.O) fell further, dropping nearly 3%.

2025-09-17

SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.

2025-09-18

HGTECH's 3.2T NPO products are used by leading industry customers

2025-09-24

Alipay's two operating entities have completed the name change

2025-09-19

ASIA TECH WIRE

Grasp technology trends

Download